A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors

This study looks at whether a blood test that measures a specific molecule called miRNA-371 can predict how well patients with newly diagnosed germ cell tumors (a type of cancer that usually starts in the testicles or ovaries) will do after treatment. Researchers want to know if this marker can help guide follow-up care decisions. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with a germ cell tumor, confirmed either by biopsy or by elevated tumor markers (HCG or AFP) in your blood - All tumor types and stages are eligible, including second primary germ cell tumors - If you have testicular cancer at an early stage requiring surgery, you must have had the orchiectomy (removal of the testicle) within 42 days before enrolling **You may NOT be eligible if...** - Your cancer is considered high risk or has spread (metastatic) - Required tests or imaging were not completed within the required timeframe Talk to your doctor to see if this trial is right for you.